Table 3.

Adverse events, morbidity, and mortality at 1-month*

Event type	All (n=167)	DL (n=80)	SL/SLS (n=87)	p Value
Thromboembolic events	24 (14.4%)	15 (18.8%)	9 (10.3%)	0.130
Asymptomatic	11 (6.6%)	9 (11.3%)	2 (2.3%)	0.027
Symptomatic without sequelae	8 (4.8%)	4 (5.0%)	4 (4.6%)	1.000
Symptomatic with sequelae	5 (3.0%)	2 (2.5%)	3 (3.4%)	1.000
Intraprocedural rupture	2 (1.2%)	1 (1.3%)	1 (1.1%)	1.000
Intracranial hemorrhage	1 (0.6%)	1 (1.3%)	0 (0.0%)	0.479
Morbidity†	5 (3.0%)	3 (3.8%)	2 (2.3%)	0.671
Mortality	0 (0.0%)	0 (0.0%)	0 (0.0%)	NA

*One patient withdrew his consent between the procedure and the 1-month follow-up.

†Modified Rankin Scale (mRS) score >2 if baseline ≤2. mRS +1 or more if baseline >2. mRS >2 and ruptured at baseline.